PHASE II STUDY OF SYNTHADOTIN (SYN-D; ILX651) ADMINISTERED DAILY FOR 5 CONSECUTIVE DAYS ONCE EVERY 3 WEEKS (QDX5Q3W) IN PATIENTS (PTS) WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC MELANOMA

EBBINGHAUS, S., HERSH, E., & CUNNINGHAM, C.C.. (2004). PHASE II STUDY OF SYNTHADOTIN (SYN-D; ILX651) ADMINISTERED DAILY FOR 5 CONSECUTIVE DAYS ONCE EVERY 3 WEEKS (QDX5Q3W) IN PATIENTS (PTS) WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC MELANOMA. JOURNAL OF CLINICAL ONCOLOGY, 22(14), 7530-7530. SID. https://sid.ir/paper/658949/en

EBBINGHAUS S., HERSH E., CUNNINGHAM C.C.. PHASE II STUDY OF SYNTHADOTIN (SYN-D; ILX651) ADMINISTERED DAILY FOR 5 CONSECUTIVE DAYS ONCE EVERY 3 WEEKS (QDX5Q3W) IN PATIENTS (PTS) WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC MELANOMA. JOURNAL OF CLINICAL ONCOLOGY[Internet]. 2004;22(14):7530-7530. Available from: https://sid.ir/paper/658949/en

S. EBBINGHAUS, E. HERSH, and C.C. CUNNINGHAM, “PHASE II STUDY OF SYNTHADOTIN (SYN-D; ILX651) ADMINISTERED DAILY FOR 5 CONSECUTIVE DAYS ONCE EVERY 3 WEEKS (QDX5Q3W) IN PATIENTS (PTS) WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC MELANOMA,” JOURNAL OF CLINICAL ONCOLOGY, vol. 22, no. 14, pp. 7530–7530, 2004, [Online]. Available: https://sid.ir/paper/658949/en